|
1）Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009; 373(9674): 1550-61
|
|
|
|
2）Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesen-chymal stem cells. Science. 1999; 284(5411): 143-7
|
|
|
|
|
|
3）Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002; 30(1): 42-8
|
|
|
|
|
|
4）Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. 2007; 109(1): 228-34
|
|
|
|
|
|
5）Oh I, Ozaki K, Sato K, et al. Interferon-gamma and NF-kappa B mediate nitric oxide production by mesenchymal stromal cells. Biochem Biophys Res Commun. 2007; 355(4): 956-62
|
|
|
|
|
|
6）Tatara R, Ozaki K, Kikuchi Y, et al. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy. 2011; 13(6): 686-94
|
|
|
|
|
|
7）Mougiakakos D, Jitschin R, Johansson CC, et al. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood. 2011; 117(18): 4826-35
|
|
|
|
|
|
8）Prockop DJ, Kota DJ, Bazhanov N, et al. Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). J Cell Mol Med. 2010; 14(9): 2190-9
|
|
|
|
|
|
9）François S, Bensidhoum M, Mouiseddine M, et al. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells. 2006; 24(4): 1020-9
|
|
|
|
|
|
10）Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesen-chymal stem cells. Lancet. 2004; 363(9419): 1439-41
|
|
|
|
|
|
11）Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Trans-plantation. 2006; 81(10): 1390-7
|
|
|
|
|
|
12）Le Blanc K, Frassoni F, Ball L, et al. Developmental Committee of the European Group for blood and marrow transplantation. mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008; 371(9624): 1579-86
|
|
|
|
|
|
13）Sato K, Ozaki K, Mori M, et al. Mesenchymal stromal cells for graft-versus-host disease: basic aspects and clinical outcomes. J Clin Exp Hematop. 2010; 50(2): 79-89
|
|
|
|
|
14）Prasad VK, Lucas KG, Kleiner GI, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant. 2011; 17(4): 534-41
|
|
|
|
|
|
15）Ozawa Y, Goto T, Ohashi K, et al. Mesenchymal stem cells as a treatment for steroid-resistant acute graft versus host disease (aGVHD); A Multicenter Phase I/II Study. Blood (ASH Annual Meeting Abstracts). 2011; 118: 304
|
|
|
|
|
|
16）Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol. 2009; 9(7): 480-90
|
|
|
|
|
|
17）Ozaki K, Spolski R, Feng CG, et al. A critical role for IL-21 in regulating immunoglobulin production. Science. 2002; 298(5598): 1630-4
|
|
|
|
|
|
18）Spolski R, Kashyap M, Robinson C, et al. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci U S A. 2008; 105(37): 14028-33
|
|
|
|
|
|
19）Bucher C, Koch L, Vogtenhuber C, et al. IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood. 2009; 114(26): 5375-84
|
|
|
|
|
|
20）Meguro A, Ozaki K, Oh I, et al. IL-21 is critical for GVHD in a mouse model. Bone Marrow Transplant. 2010; 45(4): 723-9
|
|
|
|
|
|
21）Oh I, Ozaki K, Meguro A, et al. Altered effector CD4＋ T cell function in IL-21R－/－ CD4＋ T cell-mediated graft-versus-host disease. J Immunol. 2010; 185(3): 1920-6
|
|
|
|
|
|
22）Meguro A, Ozaki K, Hatanaka K, et al. Lack of IL-21 signal attenuates graft-versus-leukemia effect in the absence of CD8 T-cells. Bone Marrow Transplant. 2011; 46(12): 1557-65
|
|
|
|
|
|
23）Hanash AM, Kappel LW, Yim NL, et al. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood. 2011; 118(2): 446-55
|
|
|
|
|
|
24）Hippen KL, Bucher C, Schirm DK, et al. Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood. 2012; 119(2): 619-28
|
|
|
|
|